Bristol-Myers to pay $2.5 billion for Inhibitex
- January 09, 2012
Bristol-Myers Squibb has agreed to pay about $2.5 billion in cash to acquire Inhibitex, the New York Times reports. Inhibitex makes a treatment for hepatitis C. The move comes as large ... Read More